Clinical Trials on Hyperlipoproteinemia Type 5 in Japan

Total 1471 results

Eli Lilly and Company

Active, not recruiting

A Study of LY3561774 in Participants With Mixed Dyslipidemia (PROLONG-ANG3)

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hyperlipoproteinemia

United States, Mexico, Poland, Canada, Turkey, Japan, Argentina
Aegerion Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy

Familial Hypercholesterolemia - Homozygous

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

Hypercholesterolemia

Japan
Regeneron Pharmaceuticals
Sanofi

Completed

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ODYSSEY HoFH)

Homozygous Familial Hypercholesterolemia

United States, South Africa, Canada, Greece, Japan, Ukraine, Austria, Czechia, France, Germany, Italy, Taiwan, Turkey
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Netherlands, Australia, Austria, Canada, France, Greece, Italy, Japan, South Africa, Ukraine
Regeneron Pharmaceuticals

Completed

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Netherlands, South Africa, Australia, Austria, Canada, Czechia, France, Greece, Italy, Japan, Ukraine
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-15)

Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia

Japan
Merck Sharp & Dohme LLC

Completed

A Study of the Efficacy and Safety of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Hypercholesterolemia | Familial Hypercholesterolemia

United States, Germany, Japan, Korea, Republic of, Mexico, Norway, Turkey, United Kingdom
Amgen

Completed

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan

Hypercholesterolemia | Familial Hypercholesterolemia

Japan
Novartis Pharmaceuticals

Recruiting

Specified Drug-use Survey of Leqvio for s.c. Injection.

Hypercholesterolaemia | Familial Hypercholesterolaemia

Japan
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Hypercholesterolemia | Familial Hypercholesterolemia

Colombia, Israel, Taiwan, United States, Argentina, China, Germany, Italy, Japan, Korea, Republic of, Mexico, South Africa, Spain, Turkey
Amgen

Completed

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG)

Severe Familial Hypercholesterolemia

Italy, Czechia, United States, Israel, New Zealand, South Africa, France, Spain, Australia, Belgium, Canada, Netherlands, Hong Kong, Brazil, United Kingdom, Greece, Japan, Lebanon
Arrowhead Pharmaceuticals

Active, not recruiting

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) (PALISADE)

Familial Chylomicronemia

Korea, Republic of, Canada, Australia, Singapore, Belgium, Spain, Japan, United States, Austria, Germany, Ireland, Oman, Poland, Israel, New Zealand, Argentina, France, Croatia, Mexico, Serbia, Turkey
Osaka University

Unknown

Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) (DAPHNIS)

Diabetes Mellitus, Type 2

Japan
Takeda

Completed

Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation (Oasis Flow)

Hyperlipidemia

Japan
NewAmsterdam Pharma

Active, not recruiting

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY)

Dyslipidemias | Hypercholesterolemia | Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease | High Cholesterol

United States, Poland, Denmark, Czechia, China, Netherlands, Japan, Georgia
Osaka University

Active, not recruiting

Efficacy of Plant-protein Diets in Patients With Chronic Kidney Disease

Chronic Kidney Disease Stage 5

Japan
Daiichi Sankyo Co., Ltd.

Completed

A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type2 Diabetes Mellitus

Japan
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma (ILUSTRO)

Gastric Cancer | Pharmacokinetics of Zolbetuximab | Gastro-esophageal Junction (GEJ) Cancer | Pharmacokinetics of Oxaliplatin | Pharmacokinetics of Fluorouracil Bolus (5-FU)

United States, Japan, Italy, Korea, Republic of, Taiwan, France
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"

Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Eli Lilly and Company

Completed

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

Type 2 Diabetes

Japan
Astellas Pharma Inc

Completed

A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Daiichi Sankyo Co., Ltd.

Completed

Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides

Surveillance

Japan
AstraZeneca

Completed

The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
Takeda

Completed

Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"

Type 2 Diabetes Mellitus

Japan
Novartis Pharmaceuticals

Completed

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Hoffmann-La Roche

Terminated

Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG

Diabetes

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Sanofi

Completed

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (GAUDI)

Type 2 Diabetes Mellitus

Japan
Niigata Medical Center
Nagaoka Red Cross Hospital

Unknown

Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

Japan
Sanofi

Completed

Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride

Type 2 Diabetes Mellitus

Japan
Takeda

Completed

Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"

Type 2 Diabetes Mellitus

Japan
Sanofi

Terminated

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise (SOLO)

Obesity | Diabetes Mellitus Type 2

Japan
Takeda

Completed

Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea

Surveillance

Japan
Kyowa Kirin Co., Ltd.

Completed

A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus

Diabetes

Japan
Saitama Medical University

Completed

Relationship Between Body Weight and Glycohemoglobin

Type 2 Diabetes Mellitus

Japan
Novo Nordisk A/S

Completed

Special Survey for Patients With Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Special Survey for Type 1 or Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Type 2 Diabetes Mellitus

Japan
Dokkyo Medical University
Merck Sharp & Dohme LLC

Unknown

Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM

Type 2 Diabetes

Japan
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Japan
Sanofi

Terminated

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug (SYMPHONY)

Obesity | Diabetes Mellitus Type 2

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Monotherapy Study of MP-513 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan

Clinical Trials on Hyperlipoproteinemia Type 5 in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations